"We are planning to pursue this each year, as long as we have products that qualify for the act...I would strongly recommend it. I have already recommended [Paradigm] to numerous business owners."

About Us 

Paradigm Partners is an international consulting firm specializing in complex federal and state tax and funding incentives, for both public and private entities, across a host of industries. Paradigm Partners has distinguished itself among its peers by adopting a low cost, high return service model that employs a tailored two-phase approach. The Company's business development and professional teams work hand in hand to provide accurate analyses, establish effective client dialogues, and guarantee rapid turnaround times.

Paradigm's staff is comprised of a highly selective pool of intellectual property and tax attorneys, engineers, PhDs, and CPAs. Company personnel utilize not only years of industry expertise, but their numerous academic achievements from distinguished institutions across the globe.

The Company's core consulting portfolio includes Global R&D Tax Credits Analyses, Hiring and Location- Based Incentives, Unemployment Claims Management, IC-DISC, Domestic Production Deduction, Grant and Non-dilutive Funding Advisory, Cost Segregation Studies, Tax Controversy, Patent and Audit Defense Services.

In the sphere of pharmaceutical drug development and therapeutic biologics (collectively, "medicine") the activities culminating in the development of a branded drug will generally not give rise to the question of whether that company is participating in qualified research eligible for the credit for increasing research activities under I.R.C. § 41 (hereinafter referred to as the R&D credit.) 

It is clear from the conception to the development of an original and innovative medication that the company is engaging in research and development of a novel product.  However, the issue lies in which of the expenses incurred during the process qualifies for the credit.  

Generally, across all industries, an investigation into the claimed activities would yield an answer as to whether or not that activity qualifies as research and development under the I.R.C.  As predicted, such an investigation is bulky and tedious, but necessary to parse through the many different activities in which a company may participate.  

However, since 2010, the IRS Large Business and International Division has been working to eliminate some of the confusion between the IRS and taxpayers with regard to the R&D credit, particularly in areas considered "core research," which includes the pharmaceutical industry.